Desogestrel

Desogestrel

SCHEMBL14071563

C#C[C@]1(O)CCC2C3CCC4=CCCCC4C3C(=C)C[C@@]21CC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PGR

The experimentally established mechanism targets of Desogestrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR known ✓ P06401 6/20 1.00
SHBG P04278 8/20 1.00
ESR1 P03372 6/20 1.00
SLC6A4 P31645 6/20 1.00
AR P10275 4/20 1.00
CHRM2 P08172 3/20 1.00
SLC6A2 P23975 3/20 1.00
NR3C1 P04150 3/20 1.00
OPRM1 P35372 2/20 1.00
NR1I2 O75469 2/20 1.00
ADORA3 P0DMS8 2/20 1.00
PTGS1 P23219 2/20 1.00
SLC6A3 Q01959 2/20 1.00
DRD1 P21728 1/20 1.00
AGTR1 P30556 1/20 1.00
CCKBR P32239 1/20 1.00
DRD3 P35462 1/20 1.00
PDE4D Q08499 1/20 1.00
KCNH2 Q12809 1/20 1.00
LMNA P02545 6/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desogestrel SCHEMBL20353079 1.00 SHBG (1.00) SHBGPGRESR1SLC6A4AR
Desogestrel SCHEMBL41341 1.00 SHBG (1.00) SHBGPGRESR1SLC6A4AR
Desogestrel SCHEMBL13575760 1.00 SHBG (1.00) SHBGPGRESR1SLC6A4AR
Desogestrel SCHEMBL28425701 0.95 SHBG (0.90) SHBGPGRESR1SLC6A4AR
Etonogestrel SCHEMBL14941286 0.92 SHBG (0.87) SHBGPGRESR1SLC6A4AR
Desogestrel SCHEMBL8853428 0.91 SHBG (0.82) SHBGPGRESR1SLC6A4AR
SCHEMBL11335079 0.89 SHBG (0.79) SHBGPGRESR1SLC6A4AR
SCHEMBL10933534 0.89 SHBG (0.79) SHBGPGRESR1SLC6A4AR
Etonogestrel SCHEMBL8731710 0.88 PGR (0.79) SHBGPGRESR1SLC6A4AR
SCHEMBL16421288 0.87 PGR (0.76) SHBGPGRESR1SLC6A4AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034716-B2 Process and new intermediates for the preparation of 11-methylene steroids CRYSTAL PHARMA, S.A.U. (ES) 2021-06-15 US disclosed
EP-3423464-B1 PROCESS AND NEW INTERMEDIATES FOR THE PREPARATION OF 11-METHYLENE STEROIDS CRYSTAL PHARMA SAU (ES) 2021-05-26 EP disclosed
US-20190092807-A1 PROCESS AND NEW INTERMEDIATES FOR THE PREPARATION OF 11-METHYLENE STEROIDS CURIA SPAIN, S.A.U. (ES) 2019-03-28 US disclosed
US-9464108-B2 Combined synthesis route for desogestrel and etonogestrel MERCK SHARP & DOHME B.V. (NL) 2016-10-11 US disclosed
US-9464108-B2 Combined synthesis route for desogestrel and etonogestrel MERCK SHARP & DOHME B.V. (NL) 2016-10-11 US disclosed
EP-2892909-B1 PROCESS FOR THE PREPARATION OF 11-METHYLENE-18-METHYLESTR-4-EN-3,17-DIONE, USEFUL AS AN INTERMEDIATE IN THE SYNTHESIS OF COMPOUNDS WITH PHARMACOLOGICAL ACTIVITY. IND CHIMICA SRL (IT) 2016-08-24 EP disclosed
US-9422326-B2 Process for preparing 11-methylene-18-methyl-estr-4-en-3, 17-dione, useful as intermediate compound for the synthesis of molecules having pharmacological activity INDUSTRIALE CHIMICA S.R.L. (IT) 2016-08-23 US disclosed
US-9422326-B2 Process for preparing 11-methylene-18-methyl-estr-4-en-3, 17-dione, useful as intermediate compound for the synthesis of molecules having pharmacological activity INDUSTRIALE CHIMICA S.R.L. (IT) 2016-08-23 US disclosed
US-20150239925-A1 Process for Preparing 11-Methylene-18-Methyl-Estr-4-En-3, 17-Dione, Useful as Intermediate Compound for the Synthesis of Molecules Having Pharmacological Activity INDUSTRIALE CHIMICA S.R.L. (IT) 2015-08-27 US disclosed
US-20150239925-A1 Process for Preparing 11-Methylene-18-Methyl-Estr-4-En-3, 17-Dione, Useful as Intermediate Compound for the Synthesis of Molecules Having Pharmacological Activity INDUSTRIALE CHIMICA S.R.L. (IT) 2015-08-27 US disclosed
US-20150031875-A1 COMBINED SYNTHESIS ROUTE FOR DESOGESTREL AND ETONOGESTREL ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2015-01-29 US disclosed
WO-2014037873-A1 PROCESS FOR PREPARING 11 -METHYLENE-18-METHYL-ESTR-4-EN-3, 17- DIONE, USEFUL AS INTERMEDIATE COMPOUND FOR THE SYNTHESIS OF MOLECULES HAVING A PHARMACOLOGICAL ACTIVITY INDUSTRIALE CHIMICA S.R.L. (IT) 2014-03-13 WO disclosed
WO-2013135744-A1 COMBINED SYNTHESIS ROUTE FOR ETONOGESTREL AND DESOGESTREL MSD OSS B.V. (NL) 2013-09-19 WO disclosed
US-20130123523-A1 METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL EVESTRA, INC. 2013-05-16 US disclosed
WO-2013071210-A1 METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL EVESTRA, INC. (US) 2013-05-16 WO disclosed
US-20130123523-A1 METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL EVESTRA, INC. 2013-05-16 US disclosed
US-7427600-B2 Active agent delivery systems and methods for protecting and administering active agents SHIRE LLC (US) 2008-09-23 US disclosed
US-7427600-B2 Active agent delivery systems and methods for protecting and administering active agents SHIRE LLC (US) 2008-09-23 US disclosed
US-20070232529-A1 mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage NEW RIVER PHARMACEUTICALS INC. (US) 2007-10-04 US disclosed
US-20070232529-A1 mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage NEW RIVER PHARMACEUTICALS INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031875-A1 COMBINED SYNTHESIS ROUTE FOR DESOGESTREL AND ETONOGESTREL CYP19A1, CYP17A1, CYP2A6 PGR 16/4885SHBG 31/4885ESR1 79/4885
US-11034716-B2 Process and new intermediates for the preparation of 11-methylene steroids CYP17A1, HSD17B11, CYP19A1 PGR 38/4885SHBG 25/4885ESR1 99/4885
US-20190092807-A1 PROCESS AND NEW INTERMEDIATES FOR THE PREPARATION OF 11-METHYLENE STEROIDS CYP19A1, CYP17A1, HSD17B11 PGR 29/4885SHBG 31/4885ESR1 79/4885
US-20130123523-A1 METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL GNRHR, CYP19A1, HSD17B11 PGR 7/4885SHBG 4/4885ESR1 26/4885
US-20070232529-A1 mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage VIP, BST2, FCGR3B PGR 2787/4885SHBG 391/4885ESR1 3363/4885
US-20150239925-A1 Process for Preparing 11-Methylene-18-Methyl-Estr-4-En-3, 17-Dione, Useful as Intermediate Compound for the Synthesis of Molecules Having Pharmacological Activity CYP19A1, HSD17B11, CYP17A1 PGR 18/4885SHBG 13/4885ESR1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.